Trial Profile
Canagliflozin as an initial therapy in subjects with type 2 diabetes mellitus and to assess the effects of Atherogenic lipids in its glycemic control.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Oct 2019
Price :
$35
*
At a glance
- Drugs Canagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 07 Oct 2019 Results investigating the regulation of serum uric acid (SUA) levels with canagliflozin in relation to diabetic parameters published in the International Journal of Clinical Pharmacology and Therapeutics
- 21 Mar 2017 Primary endpoint (changes in HbA1c levels from baseline to 3 months) has been met as per results published in the Drugs in R and D
- 21 Mar 2017 New trial record